Evidence map›Paper›PMID 28951542›Full record

ArticleNature communications2017

Priming of lineage-specifying genes by Bcl11b is required for lineage choice in post-selection thymocytes.

Satoshi Kojo, Hirokazu Tanaka, Takaho A Endo, Sawako Muroi, Ye Liu, Wooseok Seo, Mari Tenno, Kiyokazu Kakugawa, Yoshinori Naoe, Krutula Nair and 9 more

Open access · goldAbstract read
In one paragraph

Article in Nature communications, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers.

0numbers the graph read from it
0cells of the map it votes in
42citing papers in PubMed
2.3field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

42 citing papers in PubMed, 54 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Article
  6. Article
  7. Transcriptional network dynamics in early T cell development.The Journal of experimental medicine · 2024
    Review
  8. Dual role ofBlood science (Baltimore, Md.) · 2024
    Review
  9. Review
  10. A Bcl11bFrontiers in immunology · 2024
    Article
  11. Article
  12. T cells in health and disease.Signal transduction and targeted therapy · 2023
    Review
  13. Article
  14. Article
  15. A Beginner's Guide to T Cell Development.Methods in molecular biology (Clifton, N.J.) · 2023
    Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. TCF1 in T cell immunity: a broadened frontier.Nature reviews. Immunology · 2022
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors at 5 institutions in 3 countries.

Satoshi KojoLaboratory for Transcriptional Regulation, RIKEN Center for Integrative Medical Sciences (IMS), 1-7-22 Suehiro-cho, Tsurumi-ku, Yokohama, 230-0045, Japan.
Hirokazu TanakaLaboratory for Transcriptional Regulation, RIKEN Center for Integrative Medical Sciences (IMS), 1-7-22 Suehiro-cho, Tsurumi-ku, Yokohama, 230-0045, Japan.
Takaho A EndoLaboratory for Integrative Genomics, RIKEN Center for Integrative Medical Sciences (IMS), 1-7-22 Suehiro-cho, Tsurumi-ku, Yokohama, 230-0045, Japan.ORCID http://orcid.org/0000-0002-2801-2463
Sawako MuroiLaboratory for Transcriptional Regulation, RIKEN Center for Integrative Medical Sciences (IMS), 1-7-22 Suehiro-cho, Tsurumi-ku, Yokohama, 230-0045, Japan.
Ye LiuDivision of Genomic Technologies, RIKEN Center for Life Science Technologies (CLST), 1-7-22 Suehiro-cho, Tsurumi-ku, Yokohama, 230-0045, Japan.
Wooseok SeoLaboratory for Transcriptional Regulation, RIKEN Center for Integrative Medical Sciences (IMS), 1-7-22 Suehiro-cho, Tsurumi-ku, Yokohama, 230-0045, Japan.
Mari TennoLaboratory for Transcriptional Regulation, RIKEN Center for Integrative Medical Sciences (IMS), 1-7-22 Suehiro-cho, Tsurumi-ku, Yokohama, 230-0045, Japan.
Kiyokazu KakugawaLaboratory for Transcriptional Regulation, RIKEN Center for Integrative Medical Sciences (IMS), 1-7-22 Suehiro-cho, Tsurumi-ku, Yokohama, 230-0045, Japan.
Yoshinori NaoeLaboratory for Transcriptional Regulation, RIKEN Center for Integrative Medical Sciences (IMS), 1-7-22 Suehiro-cho, Tsurumi-ku, Yokohama, 230-0045, Japan.
Krutula NairLaboratory for Transcriptional Regulation, RIKEN Center for Integrative Medical Sciences (IMS), 1-7-22 Suehiro-cho, Tsurumi-ku, Yokohama, 230-0045, Japan.
Kazuyo MoroLaboratory for Innate Immune Systems, RIKEN Center for Integrative Medical Sciences (IMS), 1-7-22 Suehiro-cho, Tsurumi-ku, Yokohama, 230-0045, Japan.
Yoshinori KatsuragiDivision of Molecular Biology, Department of Molecular Genetics, Graduate School of Medical and Dental Sciences, Niigata University, Niigata, 951-8510, Japan.
Akinori KanaiDepartment of Molecular Oncology, Research Institute for Radiation Biology and Medicine, Hiroshima University, 1-2-3, Kasumi, Minami-ku, Hiroshima, 734-8553, Japan.
Toshiya InabaDepartment of Molecular Oncology, Research Institute for Radiation Biology and Medicine, Hiroshima University, 1-2-3, Kasumi, Minami-ku, Hiroshima, 734-8553, Japan.
Takeshi EgawaDepartment of Pathology and Immunology, School of Medicine, Washington University School of Medicine, 660 S Euclid, Saint Louis, 63110, MO, USA.
Byrappa VenkateshInstitute of Molecular and Cell Biology, Agency for Science, Technology and Research, Biopolis, 138673, Singapore.
Aki MinodaDivision of Genomic Technologies, RIKEN Center for Life Science Technologies (CLST), 1-7-22 Suehiro-cho, Tsurumi-ku, Yokohama, 230-0045, Japan.
Ryo KominamiDivision of Molecular Biology, Department of Molecular Genetics, Graduate School of Medical and Dental Sciences, Niigata University, Niigata, 951-8510, Japan.
Ichiro TaniuchiLaboratory for Transcriptional Regulation, RIKEN Center for Integrative Medical Sciences (IMS), 1-7-22 Suehiro-cho, Tsurumi-ku, Yokohama, 230-0045, Japan. ichiro.taniuchi@riken.jp.
RIKEN Center for Integrative Medical Sciences · JPHiroshima University · JPNiigata University · JPAgency for Science, Technology and Research · SGWashington University in St. Louis · US

Funding

GENE REGULATION GOVERNING T LYMPHOCYTE FATE DECISIONSR01AI097244 · NIAID · WASHINGTON UNIVERSITY · PI EGAWA, TAKESHI · 2012 to 2016
$1.9M
NIAID NIH HHS R01 AI097244
6 · The paper itself

Abstract

T-lineage committed precursor thymocytes are screened by a fate-determination process mediated via T cell receptor (TCR) signals for differentiation into distinct lineages. However, it remains unclear whether any antecedent event is required to couple TCR signals with the transcriptional program governing lineage decisions. Here we show that Bcl11b, known as a T-lineage commitment factor, is essential for proper expression of ThPOK and Runx3, central regulators for the CD4-helper/CD8-cytotoxic lineage choice. Loss of Bcl11b results in random expression of these factors and, thereby, lineage scrambling that is disconnected from TCR restriction by MHC. Initial Thpok repression by Bcl11b prior to the pre-selection stage is independent of a known silencer for Thpok, and requires the last zinc-finger motif in Bcl11b protein, which by contrast is dispensable for T-lineage commitment. Collectively, our findings shed new light on the function of Bcl11b in priming lineage-specifying genes to integrate TCR signals into subsequent transcriptional regulatory mechanisms.CD4 and CD8 T cells develop in the thymus with their transcription programs controlled by ThPOK and Runx3, respectively. Here the authors show that a pre-commitment event modulated by the transcription factor, Bcl11b, is required for the proper expression of ThPOK and Runx3 and correct CD4/CD8 lineage commitment.

Indexed as

AnimalsCell DifferentiationCell LineageCore Binding Factor Alpha 3 SubunitGene Expression RegulationMiceReceptors, Antigen, T-CellRepressor ProteinsThymocytesT-Lymphocytes, CytotoxicT-Lymphocytes, Helper-InducerTranscription FactorsTumor Suppressor ProteinsBcl11b protein, mouseCore Binding Factor Alpha 3 SubunitReceptors, Antigen, T-CellRepressor ProteinsRunx3 protein, mouseTranscription FactorsTumor Suppressor ProteinsZbtb7b protein, mouse

Identifiers

PMID28951542
PMCPMC5615048
OpenAlexW2754962524

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.